期刊文献+

OATP_1B_1388G>A基因多态性对阿托伐他汀调脂疗效的影响

下载PDF
导出
摘要 目的观察有机阴离子转运多肽1B1388G>A基因多态性对阿托伐他汀调脂疗效的影响。方法样本收集105例应用阿托伐他汀治疗的高脂血症患者,阿托伐他汀(20mg,1日1次)连续治疗,分别于治疗前及治疗开始后第四周抽血实验室检查血脂指标。用聚合酶链反应限制性片段长度多态性(PCR-RFLPs)方法分析(OATP1B1388G>A)基因多态性;用高效液相色谱法测定阿托伐他汀血药浓度(稳态谷浓度)比较调脂疗效。结果 105例高脂血症患者中,OATP1B1388G>A等位基因的突变频率为69.05%。阿托伐他汀对OATP1B1388G>A等位基因型间患者TC、TG、HDL-C、及LDL-C的影响均无显著差异。但突变型纯合子组患者稳态血药浓度明显高于突变型杂合子与野生型纯合子(P<0.05)。结论 OATP1B1388G>A基因位点的变异对阿托伐他汀的调脂疗效无影响。
出处 《海峡药学》 2014年第6期108-109,共2页 Strait Pharmaceutical Journal
  • 相关文献

参考文献7

  • 1Hsiang B,Zhu Y,Wang Z,et al.A novel human hepatic organic anion transporting polypeptide(OATP2).Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters[J].J Biol Chem,1999,274(52):37161-37168.
  • 2Rodrigues AC.Efflux and uptake transporters as determinants of statin response[J].Expert Opin Drug Metab Toxicol,2010,6(5):621-632.
  • 3Nishizato Y,Ieiri I,Suzuki H,et al.Polymorphisms of OATP-C(SLC21A6)and OAT3(SLC22A8)genes:consequences for pravastatin pharmacokinetics[J].ClinPharmacol Ther,2003,73(6):554-565.
  • 4Tirona RG,Kim RB.Pharmacogenomics of organic anion-transporting polypeptides(OATP)[J].Adv Drug Deliv Rev,2002,54(10):1343-1352.
  • 5Zair ZM,Eloranta JJ,Stieger B,et al.Pharmacogenetics of OATP(SLC21/SLCO),OAT and OCT(SLC22)and PEPT(SLC15)transporters in the intestine,liver and kidney[J].Pharmacogenomics,2008,9(5):597-624.
  • 6Zhang W,Yu BN,He YJ,et al.Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males[J].Clin Chim Acta,2006,373(1-2):99-103.
  • 7Noe J,Portmann R,Brun ME,et al.Substrate-dependent drug-drug interactions between gemfibrozil,fluvastatin and other organic aniontransporting peptide(OATP)substrates on OATP1B1,OATP2B1,and OATP1B3[J].Drug Metab Dispos,2007,35(8):1308-1314.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部